Antisoma news from FierceBiotech
NewsAntisoma buys Xanthus for $52M
Looking to boost its pipeline, the U.K.'s Antisoma is paying $52 million for Boston oncology company Xanthus Pharmaceutical. Antisoma gains three drug candidates:Xanafide, which is in Phase III trial Read more...
Antisoma starts licensing spree with cancer deal
Bankrolled by a $125 million licensing deal with Novartis, the UK's Antisoma has turned around and used part of its Read more...
Antisoma scouts for new therapies to add to pipeline
Antisoma is sending out signals that it's looking for new acquisitions to add to its pipeline. "With a strong balance sheet, we are well placed to invest in and add value to our current pipeline and Read more...
UK biotechs feeling the chill from investors
One of the analysts at Seymour Pierce has been pondering the ice-cold attitude of investors to biotech stocks in the UK. Despite some big licensing news for the likes of Read more...
Antisoma shares tank on bold new trial strategy
Shares of Antisoma took a dive this morning after researchers announced that they would pit ASA404 against Roche and Read more...
2. Novartis and Antisoma
Who: Novartis With: Antisoma What: $890 million licensing deal Summary: With money from the sale of two major divisions Read more...
Antisoma shares spike on positive cancer data
Antisoma saw its shares spike on positive data from a trial in non-small cell lung cancer. "These positive results strongly support our earlier trial findings, which showed that adding ASA404 Read more...
Antisoma drug flunks ovarian cancer trial
The UK's Antisoma says that its experimental therapy for ovarian cancer has failed a clinical trial, triggering a swift loss of about one fifth of the company's share value. The mid-stage trial of Read more...
Press Release: data from Antisoma’s AS1404 lung cancer trial show clear survival benefitPress Release: data from Antisoma’s AS1404 lung cancer trial show clear survival benefit Read more...Antisoma adds more positive data for AS1404Antisoma is adding more positive data for its closely-watched lung cancer therapy AS1404. Lung cancer patients taking the treatment with chemotherapy experienced greater delays for tumor progression than had been reported earlier. In the trial, tumor response rates hit 31 percent with AS1404 as compared to 22 percent for chemo alone. Antisoma has been in talks to sign a licensing partner for the therapy, which is headed for Phase III next year. Antisoma says AS1404 can compete with … Read more... | Press ReleasesPRESS RELEASE: Antisoma Shares Slide as Novartis Corporation (NVS) Sets up Avastin Fight Antisoma Shares Slide as Novartis Corporation Sets up Avastin Fight LONDON--Nov 20, 2007 -- ASA404 phase III lung cancer trial to include broader range of patients London, UK: 20 November 2007 - Read more... |
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends